论文部分内容阅读
目的:探讨接受舒尼替尼治疗的胰腺神经内分泌瘤患者的临床特征、治疗和预后影响因素。方法:回顾性分析2013—2017年入组中国癌症基金会索坦项目援助项目的235例胰腺神经内分泌瘤患者的临床资料，分析患者的临床病理特征、治疗情况和预后影响因素。结果:235例患者的总生存时间为4～252个月，3和5年生存率分别为73.8%和60.8%。单因素分析显示，确诊年龄、Ki-67阳性指数和手术与胰腺神经内分泌瘤患者的3年生存率均有关(均n P<0.05)。多因素分析结果显示，确诊年龄、Ki-67阳性指数和手术是影响胰腺神经内分泌瘤患者生存的独立因素(均n P<0.05)。对于肝转移患者，手术与患者的预后有关(n P<0.05)。124例长期服用舒尼替尼患者的5年生存率为53.3%。n 结论:胰腺神经内分泌瘤临床少见，起病症状多不典型，多数患者在就诊时已发生转移，预后相对较好。年龄、Ki-67阳性指数和手术可影响胰腺神经内分泌瘤患者的预后。“,”Objective:To investigate the clinical characteristics, treatment, and prognostic factors of pancreatic neuroendocrine tumors (pNETs) patients treated with Sunitinib.Methods:The clinical data of pNETs patients from Pfizer Drug Assistance Program of Cancer Foundation of China from April 2013 to November 2017 were retrospectively analyzed. Follow-up and statistical analysis were performed.Results:A total of 235 patients were enrolled, the patients′ overall survival time was between 4 and 252 months, the 3-years and 5-years survival rates were 73.8% and 60.8%, respectively. Univariate analysis showed that factors such as age, Ki-67 index and surgery were associated with the 3-years survival rates of pNETs patients (n P<0.05). Multivariate analysis demonstrated that the age, Ki-67 index and surgery were independent prognostic factors for pNETs patients (n P<0.05). For patients with liver metastases, univariate analysis revealed that surgery was associated with prognosis (n P<0.05). The 5-years survival rate of 124 patients with extending usage of Sunitinib was 53.3%.n Conclusion:PNETs are rare tumors with atypical clinical symptoms and the patients often have metastasis at the initiate diagnosis. The age, Ki-67 index and surgery are associated with the prognosis of pNETs patients.